EA036704B1 - Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита - Google Patents

Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита Download PDF

Info

Publication number
EA036704B1
EA036704B1 EA201692050A EA201692050A EA036704B1 EA 036704 B1 EA036704 B1 EA 036704B1 EA 201692050 A EA201692050 A EA 201692050A EA 201692050 A EA201692050 A EA 201692050A EA 036704 B1 EA036704 B1 EA 036704B1
Authority
EA
Eurasian Patent Office
Prior art keywords
nash
nafld
mbx
treatment
alcoholic
Prior art date
Application number
EA201692050A
Other languages
English (en)
Russian (ru)
Other versions
EA201692050A1 (ru
Inventor
Брайан Робертс
Сюэянь Ванг
Юнь-Цзюн Чой
Дэвид Карпф
Роберт Мартин
Чарльз А. Макуэртер
Original Assignee
Саймабэй Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA036704(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Саймабэй Терапьютикс, Инк. filed Critical Саймабэй Терапьютикс, Инк.
Publication of EA201692050A1 publication Critical patent/EA201692050A1/ru
Publication of EA036704B1 publication Critical patent/EA036704B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
EA201692050A 2014-04-11 2015-04-10 Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита EA036704B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11
PCT/US2015/025416 WO2015157697A1 (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Publications (2)

Publication Number Publication Date
EA201692050A1 EA201692050A1 (ru) 2017-01-30
EA036704B1 true EA036704B1 (ru) 2020-12-10

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692050A EA036704B1 (ru) 2014-04-11 2015-04-10 Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита

Country Status (27)

Country Link
US (7) US9381181B2 (enExample)
EP (1) EP3129018B1 (enExample)
JP (1) JP6865038B2 (enExample)
KR (1) KR102374499B1 (enExample)
CN (1) CN106163508A (enExample)
AU (1) AU2015243239B2 (enExample)
BR (1) BR112016023269A8 (enExample)
CA (1) CA2944139C (enExample)
CL (1) CL2016002517A1 (enExample)
CY (1) CY1122602T1 (enExample)
DK (1) DK3129018T3 (enExample)
EA (1) EA036704B1 (enExample)
ES (1) ES2764467T3 (enExample)
HR (1) HRP20192299T1 (enExample)
IL (1) IL248193B (enExample)
LT (1) LT3129018T (enExample)
MX (1) MX369921B (enExample)
NZ (1) NZ724740A (enExample)
PH (1) PH12016501978B1 (enExample)
PL (1) PL3129018T3 (enExample)
PT (1) PT3129018T (enExample)
RS (1) RS59637B1 (enExample)
SG (1) SG11201608077PA (enExample)
SI (1) SI3129018T1 (enExample)
SM (1) SMT202000019T1 (enExample)
UA (1) UA121208C2 (enExample)
WO (1) WO2015157697A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5924834B2 (ja) 2008-09-02 2016-05-25 アマリン ファーマシューティカルズ アイルランド リミテッド エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法
KR20110091680A (ko) * 2008-10-17 2011-08-12 메타볼렉스, 인코포레이티드 작고 조밀한 ｌｄｌ 입자를 감소시키는 방법
NZ734905A (en) 2009-04-29 2019-05-31 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
HUE034941T2 (en) 2009-04-29 2018-03-28 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition and methods of using same
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
MX392694B (es) 2012-06-29 2025-03-24 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP6568577B2 (ja) 2014-03-20 2019-08-28 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 肝内胆汁うっ滞症の治療
PH12016501978B1 (en) * 2014-04-11 2023-07-12 Cymabay Therapeutics Inc Treatment of nafld and nash
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CA2980296A1 (en) * 2015-03-26 2016-09-29 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
KR20240033300A (ko) 2015-04-28 2024-03-12 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
WO2017192997A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
EP3534919A4 (en) * 2016-11-04 2020-11-11 Children's Hospital Medical Center Liver organoid compositions and methods of making and using same
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
KR102807995B1 (ko) 2016-12-05 2025-05-16 칠드런즈 호스피탈 메디칼 센터 결장 유사장기 및 이를 제조 및 사용하는 방법
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
US11000491B2 (en) 2017-05-05 2021-05-11 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2019053582A1 (en) 2017-09-13 2019-03-21 Novartis Ag COMBINATIONS HAVING FXR AGONISTS
CA3077442A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
WO2019083070A1 (ko) * 2017-10-27 2019-05-02 주식회사 삼양사 비알코올성 지방간 질환의 예방 또는 개선용 조성물
BR112020011431A2 (pt) 2017-12-06 2020-11-24 Basf As derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
SG11202100533VA (en) 2018-07-26 2021-02-25 Childrens Hospital Med Ct Hepato-biliary-pancreatic tissues and methods of making same
WO2020056158A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
JP7020756B2 (ja) 2018-09-24 2022-02-16 アマリン ファーマシューティカルズ アイルランド リミテッド 対象の心血管イベントのリスクを低減する方法
CA3118965A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
SG11202104951RA (en) * 2018-11-16 2021-06-29 Cymabay Therapeutics Inc Combination treatment of nafld and nash
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CA3141807A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021097120A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US20210145774A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
US20210379043A1 (en) * 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
AU2022274304A1 (en) * 2021-05-11 2023-10-26 Genfit Ppar-agonists for use in the treatment of liver failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033231A2 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica N.V. Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JPH10512894A (ja) 1995-03-06 1998-12-08 アイシス・ファーマシューティカルス・インコーポレーテッド ２’−ｏ−置換ピリミジンおよびそのオリゴマー化合物の合成の改良法
ATE267207T1 (de) 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7301050B2 (en) 2003-09-19 2007-11-27 Janssen Pharmaceutical N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
HRP20130115T4 (hr) 2004-03-05 2016-04-22 The Trustees Of The University Of Pennsylvania Postupci liječenja poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperkolesterolemijom uz minimizaciju sporednih efekata
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
KR20110091680A (ko) 2008-10-17 2011-08-12 메타볼렉스, 인코포레이티드 작고 조밀한 ｌｄｌ 입자를 감소시키는 방법
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CA2930069A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
JP6568577B2 (ja) 2014-03-20 2019-08-28 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 肝内胆汁うっ滞症の治療
PH12016501978B1 (en) 2014-04-11 2023-07-12 Cymabay Therapeutics Inc Treatment of nafld and nash
US20150374649A1 (en) 2014-06-26 2015-12-31 Cymabay Therapeutics, Inc Treatment of Severe Hypertriglyceridemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033231A2 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica N.V. Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAYS HAROLD E ET AL: "MBX-8025, A Novel Peroxisome Proliferator Receptor-delta Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 96, no. 9, 13 June 2012 (2012-06-13), US, pages 2889 - 2897, XP002677652, ISSN: 0021-972X *
SAHEBKAR, AMIRHOSSEIN; CHEW, GERARD T.; WATTS, GERALD F.: "New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease", EXPERT OPIN PHARMACOTHER, ASHLEY PUBLICATIONS LTD, LONDON, UK, vol. 15, no. 4, 1 March 2014 (2014-03-01), London, UK, pages 493 - 503, XP009182172, ISSN: 1465-6566, DOI: 10.1517/14656566.2014.876992 *

Also Published As

Publication number Publication date
NZ724740A (en) 2019-11-29
US10342770B2 (en) 2019-07-09
CY1122602T1 (el) 2021-03-12
US20180228752A1 (en) 2018-08-16
SG11201608077PA (en) 2016-10-28
AU2015243239B2 (en) 2019-11-14
UA121208C2 (uk) 2020-04-27
DK3129018T3 (da) 2020-01-20
PH12016501978A1 (en) 2016-12-19
US20180008566A1 (en) 2018-01-11
US20210038546A1 (en) 2021-02-11
US20200009092A1 (en) 2020-01-09
RS59637B1 (sr) 2020-01-31
IL248193B (en) 2019-03-31
EP3129018B1 (en) 2019-10-23
EP3129018A1 (en) 2017-02-15
JP6865038B2 (ja) 2021-04-28
US11179359B2 (en) 2021-11-23
BR112016023269A2 (pt) 2017-08-15
SI3129018T1 (sl) 2020-02-28
US9381181B2 (en) 2016-07-05
PL3129018T3 (pl) 2020-05-18
MX2016013375A (es) 2017-02-15
KR102374499B1 (ko) 2022-03-14
HRP20192299T1 (hr) 2020-03-06
US9962346B2 (en) 2018-05-08
KR20160136451A (ko) 2016-11-29
US9616039B2 (en) 2017-04-11
US20190142776A1 (en) 2019-05-16
US10722483B2 (en) 2020-07-28
PT3129018T (pt) 2020-01-15
CA2944139A1 (en) 2015-10-15
ES2764467T3 (es) 2020-06-03
CL2016002517A1 (es) 2017-05-05
PH12016501978B1 (en) 2023-07-12
AU2015243239A1 (en) 2016-10-20
US20160324812A1 (en) 2016-11-10
BR112016023269A8 (pt) 2021-06-29
JP2017513836A (ja) 2017-06-01
US20150290154A1 (en) 2015-10-15
LT3129018T (lt) 2020-01-10
SMT202000019T1 (it) 2020-03-13
WO2015157697A1 (en) 2015-10-15
US10188620B2 (en) 2019-01-29
EA201692050A1 (ru) 2017-01-30
CN106163508A (zh) 2016-11-23
CA2944139C (en) 2020-11-03
MX369921B (es) 2019-11-26

Similar Documents

Publication Publication Date Title
US11179359B2 (en) Treatment of NAFLD and NASH
JP6568577B2 (ja) 肝内胆汁うっ滞症の治療
WO2020102351A1 (en) Treatment of obesity and its complications
KR20210092754A (ko) Nafld 및 nash의 병용 치료
KR102408288B1 (ko) 간내 담즙 정체성 질환의 치료
HK1228275A1 (en) Treatment of nafld and nash
HK1228275B (en) Treatment of nafld and nash